Drugs / Sabestomig
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT06366451 | May 2024 → Mar 2026 | head and neck squamous cell carcinoma | Presage Biosciences | Completed | No outcome recorded |
| Phase 0 | NCT04541108 | Jul 2021 → Dec 2031 expected | cancer | Presage Biosciences | Active not recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT05216835 | Mar 2022 → Aug 2024 | classic Hodgkin lymphoma | AstraZeneca | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-11-29 | AstraZeneca | Results AstraZeneca advances scientific leadership in haematology at ASH 2023 astrazeneca.com ↗
We will also present the first clinical data on sabestomig, a PD-1/TIM-3 targeting bispecific antibody, in R/R Hodgkin lymphoma, showing encouraging early signals of activity. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-11-29 | AstraZeneca | AstraZeneca advances scientific leadership in haematology at ASH 2023 astrazeneca.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sabestomig | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06366451 ↗ |
| Known as | AZD7789 | “Sabestomig (AZD7789)” NCT05216835 ↗ |
| Modality | Monoclonal antibody | — CHEMBL5314771 ↗ |
| Route | Other | “Intratumoral microdose injection by the CIVO device.” NCT06366451 ↗ |